Forecast

The analysts' average price target is +19,66€ (+73,22%). The median is +20,61€ (+81,59%).

Buy	15
Hold	2
Sell	0

News Go to news feed

Kura Oncology CEO Troy Edward Wilson buys ~100,000 shares for $1.2 million

Troy Edward Wilson purchased about 100,000 Kura Oncology shares on Aug. 24, 2026 at a weighted average price of $12.39, a $1.2 million transaction that raises his total beneficial ownership to roughly 1.2 million shares. The purchase increases his stake by about 9% and includes holdings via the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. The trade occurred with Kura Oncology at a $1.1 billion market cap; the company reported TTM revenue of $77.2 million and a net loss of $296.8 million. The article frames the insider buy as a potentially bullish signal for the stock. » More on finance.yahoo.com
Kura Oncology: CEO insider buys and analyst praise push stock higher

Kura Oncology shares jumped sharply in premarket trading after CEO Troy Edward Wilson bought 100,000 common shares on August 24, 2026 through a trust at a weighted average price of $12.39 — his second large purchase within a week, raising his economic ownership to 479,194 shares (plus 300,000 shares in a foundation). Citizens affirmed a "Market Outperform" rating with a $24.00 price target, and Jefferies also reiterated a buy recommendation. Kura also reported an adjusted Q2 loss of $0.77 per share (better than the $0.88 estimate) and revenue of $20.87 million (above expectations), boosting the positive market reaction; the stock climbed above its 52-week high of $12.90. » More on de.investing.com
Kura Oncology reaches 52‑week high after positive quarterly results and insider purchase

Kura Oncology’s stock rose to a 52‑week high of 12.49 USD and is currently trading at 12.64 USD, implying a market capitalization of around 1 billion USD. For the second quarter of 2026 the company reported an adjusted loss of 0.77 USD per share on revenue of 20.87 million USD, beating Wall Street estimates. The stock is up about 56.9% year‑to‑date; seven analysts raised their estimates, while an analysis by InvestingPro points to possible overvaluation. CEO Troy Edward Wilson made an insider purchase of 100,000 shares at a weighted average price of 11.12 USD per share, executed in multiple trades. » More on de.investing.com

Financials

In the last quarter, Kura Oncology had revenue of 18.29m€ and net profit of −59.87m€

(EUR)	Jun 2026	YoY
Revenue	+18.29m	41,01%
Gross profit	+18.08m	39,37%
Net profit	−59.87m	6,72%
EBITDA	−57.49m	3,44%

Fundamentals

Metric	Value
Market capitalization	+995.55m€
Number of shares	88.77m
52-week high/low	+11,94€ - +6,32€
Dividends	No
Beta	0,38
P/E ratio	−3,88
PEG ratio	+0,10
P/B ratio	+23,96
P/S ratio	+15,01

Company profile

Kura Oncology, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt Medikamente zur Behandlung von Krebs in den Vereinigten Staaten. Die Pipeline des Unternehmens besteht aus niedermolekularen Produktkandidaten, die gegen Krebs gerichtet sind. Die führenden Produktkandidaten sind Ziftomenib, ein niedermolekularer Inhibitor der Menin-Lysin-K-spezifischen Methyltransferase 2A-Protein-Protein-Interaktion zur Behandlung genetisch definierter Untergruppen akuter Leukämien, einschließlich akuter myeloischer Leukämie und akuter lymphatischer Leukämie, und Tipifarnib, ein oral bioverfügbarer Inhibitor der Farnesyltransferase, der sich in klinischen Phase-II-Studien zur Behandlung solider Tumore und hämatologischer Indikationen befindet. Das Unternehmen unterhält eine klinische Zusammenarbeit mit Novartis, um die Kombination von Tipifarnib und Alpelisib bei Patienten mit Plattenepithelkarzinomen des Kopfes und Halses zu untersuchen, deren Tumore eine HRAS-Überexpression oder eine PIK3CA-Mutation und/oder -Amplifikation aufweisen. Kura Oncology, Inc. wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.